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Abstract 
Context Anorexia is a problem of paramount importance in patients with advanced liver failure. Ghrelin has 
important actions on feeding and weight homeostasis. Experimental data exist, which suggest that ghrelin 
could protect hepatic tissue. Both fasting and post-oral glucose tolerance test (OGTT) ghrelin concentrations 
are controversial in liver cirrhosis and are unknown after liver transplantation.  
Objective Our aim was to study fasting ghrelin concentrations and their response to an OGTT in liver failure 
patients before and after liver transplantation.  
Design and methods We included 21 patients with severe liver failure studied before (pretransplantation, 
PreT) and 6 months after liver transplantation (posttransplantation, PostT), and 10 age- and body mass index-
matched healthy or overweight subjects as the control group (Cont). After an overnight fast, 75 g of oral 
glucose were administered; glucose, insulin, and ghrelin were obtained at baseline and at times 30, 60, 90, 
and 120 min.  
Results Fasting ghrelin (median and range, pg/ml) levels were lower in PreT: 539 (309–1262) than in Cont: 
643 (523–2163), P=0.045. Fasting ghrelin levels increased after liver transplantation, 539 (309–1262) vs 910 
(426–3305), for PreT and PostT respectively, P=0.001. The area under the curve (AUC) of ghrelin 
(pg/ml min) was lower in PreT: 63 900 (37 260–148 410) than in Cont: 76 560 (56 160–206 385), P=0.027. The 
AUC of ghrelin increased in PostT, 63 900 (37 260–148 410) vs 107 595 (59 535–357 465), for PreT and PostT 
respectively, P=0.001. Fasting levels and the AUC of ghrelin were similar in PosT and Cont.  
Conclusions Decreased fasting and post-OGTT ghrelin levels in liver failure patients were normalized after 
liver transplantation.  
 
 
 
 
 
 
 
  
Introduction 
Malnutrition is common in patients with liver failure, with a reported prevalence as high as 
80% depending on the severity of liver disease (1, 2). The mechanisms of malnutrition in cirrhosis 
are not fully understood. Anorexia is a problem of paramount importance in patients with 
advanced cirrhosis, contributing to malnutrition. In turn, malnutrition is a risk factor for the 
development of life-threatening complications and increased mortality (3, 4). 
 
Ghrelin is a 28-amino acid peptide, predominantly produced by the stomach (5, 6). Apart from 
stimulating GH secretion, ghrelin has other endocrine and nonendocrine actions (7). Different 
studies suggest the importance of ghrelin in feeding and weight homeostasis (8-13). Circulating 
plasma ghrelin increases before a meal and decreases following the consumption of nutrients and 
after an oral glucose tolerance test (OGTT) (14-16). There are two major circulating forms of 
ghrelin: acylated and des-acyl ghrelin (7). Acylated ghrelin has proved to be highly relevant in the 
development of metabolic disturbances, although total ghrelin has a well-established correlation 
with metabolic disturbances. In fact, most of the leading studies on the correlation between 
metabolic disturbances and ghrelin have focused on the estimation of total ghrelin (10-11, 13-15), 
and there are concerns about the specificity of available acyl-ghrelin assays (17). We focused on 
measuring total ghrelin, with the aim of comparing our data with the discrepant total ghrelin levels 
that have been found in hepatic failure patients in different studies (18-24).  
 
Experimental data exists that suggests that ghrelin could protect hepatic tissue. A ghrelin 
analog, GHRP-2, has a protective effect on the liver in rats, which seems to be mediated by 
insulin-like growth factor 1 (IGF1), tumour necrosis factor α (TNFα), and nitric oxide (25). 
Ghrelin alleviates biliary obstruction-induced chronic hepatic injury in rats (26). Ghrelin treatment 
ameliorates pancreaticobiliary inflammation and remote organ injury in rats (27). Taking all these 
data into account, decreased ghrelin levels could be a contributing factor for the deterioration of 
liver function in cirrhosis.  
 
Basal concentrations of ghrelin have been reported to be deranged in liver cirrhosis, but the 
results are controversial. Normal, increased, and decreased ghrelin levels have been found in 
hepatic failure patients (18-23). We have previously found significantly decreased fasting and 
post-OGTT plasma ghrelin levels in patients with liver failure who were candidates for 
transplantation when compared with control subjects (Cont) (24).  
 
In order to clarify the controversy over ghrelin levels in hepatic failure, our aim was to study 
fasting circulating ghrelin levels and their response to an OGTT in liver failure patients before and 
after liver transplantation.  
Patients and methods 
Patients 
We included 21 patients (14 males and 7 females) with liver failure prior to liver 
transplantation, with a median (range) age of 56.0 (23-48) years and a median (range) body mass 
index (BMI) of 27.5 (18.6–33.7) kg/m2. As a Cont group, ten age- and BMI-matched healthy or 
overweight subjects (six males and four females) were included, selected from a pool of volunteers 
available to our unit, were included, with a median (range) age of 58.5 (54–65) years and a median 
(range) BMI of 26.4 (20–29.7) kg/m2. The diagnosis of liver cirrhosis was either established 
histologically, or based on its clinical, laboratory, endoscopic, or imaging features, or both. The 
severity of liver disease was assessed according to Child-Pugh and the model for end-stage liver 
disease (MELD) scores. The causes of liver cirrhosis were the following: in ten patients, alcohol 
was the primary cause of the disease; in four patients, the cause was viral hepatitis (hepatitis B in 
two cases; hepatitis C in two cases); in five patients, the cause was hepatocellular carcinoma; in 
one patient the cause was primary biliary cirrhosis; in one patient, the cause was primary 
sclerosing cholagitis. At the time of the study, the patients with alcoholic liver disease had 
abstained from alcohol for 6 months or more. All cases had routine biochemical investigation, an 
ultrasound scan of the liver, and a gastrointestinal endoscopy. Among the patients with liver 
failure prior to liver transplantation, there were six patients who had been diagnosed with diabetes 
mellitus prior to the study protocol, who were being treated with dietetic therapy. All patients were 
ambulatory. Liver transplantation was performed according to the well-established clinical 
protocol in our hospital, with all the patients receiving a liver transplant from a cadaver donor. All 
patients received identical intraoperative and postoperative care. Immunosuppression was 
performed with prednisone and a calcineurin inhibitor drug (cyclosporine or tacrolimus).  
Study procedure 
Between 0830 and 0900 h, after an overnight fast and while seated, a peripheral venous line 
was obtained. Fifteen minutes later, 75 g of oral glucose was administered. We obtained blood 
samples for glucose, insulin, and ghrelin at baseline (fasting), and then at 30, 60, 90, and 120 min. 
Basal levels of GH and IGF1 were also measured. All blood samples were immediately 
centrifuged, separated, and frozen at −80 °C. Samples destined to be used for the determination of 
plasma ghrelin were specifically retrieved in chilled tubes containing aprotinin and EDTA-Na, and 
then immediately centrifuged at 4 °C, separated to aliquots, and frozen at −80 °C. All the studies 
were carried out in accordance with the Declaration of Helsinki. The study protocol was approved 
by our centre's ethical committee, and written informed consent was obtained from all patients and 
controls. The OGTT was carried out prior to liver transplantation and 6 months after. Fasting 
levels were obtained prior to liver transplantation and 1, 3, 6, and 12 months after.  
Assays 
Plasma glucose (mg/dl) was measured with an automatic glucose oxidase method (Roche 
Diagnostics). Insulin (μU/ml) was measured with a solid-phase two-site chemiluminescent 
immunometric assay (Immulite 2000 Insulin, DPC, Los Angeles, CA, USA) and with intrassay 
coefficients of variation (CV) of 5.5, 3.3, and 3.7% for low, medium, and high plasma insulin 
levels respectively. Serum GH (μg/l) was measured by a solid-phase, two-site chemiluminescent 
enzyme immunometric assay (Immulite, EURO/DPC) with a sensitivity of 0.01 μg/l and with 
intrassay CV of 5.3, 6.0, and 6.5% for low, medium, and high plasma GH levels respectively. 
IGF1 (ng/ml) was determined by a chemiluminescence assay (Nichols Institute, San Clemente, 
CA, USA) and with intrassay CV of 4.8, 5.2, and 4.4% for low, medium, and high plasma IGF1 
levels respectively. Total ghrelin (pg/ml) was measured by a commercially available RIA (Linco 
Research Inc., St Charles, MO, USA), specific for total ghrelin, which uses 
125
I-labeled ghrelin 
tracer and rabbit antighrelin serum with a specificity of 100%, with an intrassay CV of between 
4.4 and 10%.  
 
All the samples from a given subject were analyzed in the same assay run. The area under the 
secretory curve (area under the curve, AUC) was calculated by a trapezoidal method. Insulin 
resistance was calculated on the basis of fasting values of plasma glucose and insulin, according to 
the homeostasis model assessment (HOMA-IR) method (28) as follows: HOMA-IR=fasting 
insulin levels×fasting glucose levels/22.5, where basal insulin levels are in μU/ml, and glucose is 
in mmol/l.  
  
Statistical analysis 
The results are presented as median (range). All comparisons were based on univariate, 
nonparametric tests. Intragroup comparisons were based on Wilcoxon signed rank test. 
Comparisons between patients and controls were based on Mann–Whitney U test. Numerical 
correlations were analyzed using Spearman's correlation test. P values ≤0.05 were considered to be 
significant. For graphical presentation, we use mean values ±s.e.m. Version 12 of the SPSS 
software (Chicago, IL, USA) was used for the statistical analysis.  
Results 
The basic characteristics of the healthy Cont group and patients are shown in Table 1. The 
severity of liver disease was (median and range), according to Child-Pugh: 9 (5-12) and the 
MELD: 14 (7-23). Albumin (median and range) was decreased in liver failure patients when 
compared with the Cont group, 3.0 (2.6–4.6) vs 4.1 (3.4–5.3) g/dl, P=0.009.  
Table 1 Basic characteristics of control subjects and liver failure patients pretransplantation 
(median and range). 
 Controls Liver failure patients 
   
Male/female (number) 6/4 14/7 
Age (years) 58.5 (54–65) 56.0 (23–66) 
BMI (kg/m2)  26.4 (20–29.7) 27.5 (18.6–33.7) 
MELD score 
 
14 (7–23) 
Child-Pugh score 
 
9 (5–12) 
Albumin (g/dl) 4.1 (3.4–5.3) 3.0 (2.6–4.6)* 
Bilirubin (mg/dl) 0.5 (0.4–0.9) 2.8 (0.5–12.7)* 
Etiology 
  
Alcoholic 
 
10 
Viral 
 
4 
Hepatocellular carcinoma 
 
5 
PBC 
 
1 
PSC 
 
1 
   
 
BMI, body mass index; MELD, model for end-stage liver disease; PBC, primary biliary 
cirrhosis; PSC, primary sclerosing cholagitis. *P<0.01 between patients and controls. 
Fasting serum levels 
The fasting serum levels presented (Table 2) are Cont, pretransplantation (PreT), and 6th 
month after transplantation (posttransplantation, PostT) values. Fasting glucose and insulin 
(median and range) were similar in the PreT and in the Cont group, basal glucose 101 (62–177) vs 
95 (89–109) mg/dl, P=NS; fasting insulin 8.5 (1.0–159) vs 5.1 (2-12) μU/ml, P=NS, for patients 
and controls respectively. Fasting glucose and insulin (median and range) were similar in the PreT 
and PostT patients, basal glucose 101 (62–177) vs 98 (71–226) mg/dl, P=NS; fasting insulin 8.5 
(1.0–159) vs 8.2 (3.7–37.3) μU/ml, P=NS, for liver failure patients prior to liver transplantation 
and after liver transplantation respectively. Fasting insulin levels were higher in the PosT than in 
the Cont group.  
Table 2 Fasting and post OGTT biochemical and hormonal data (median and range) in Cont, PreT, and 6th month PostT 
patients. 
 
Cont PreT PostT 
    
BMI (kg/m2)  26.4 (20–29.7) 27.5 (18.6–33.7) 27.0 (17.6–36.0) 
Albumin (g/dl) 4.1 (3.4–5.3)† 3.0 (2.6–4.6) 4.4 (3.9–5.1)§ 
Bilirubin (mg/dl) 0.5 (0.4–0.9)† 2.8 (0.5–12.7) 0.8 (0.4–2.2)§ 
Fasting glucose 95 (89–109) 101 (62–177) 98 (71–226) 
Fasting insulin (μUI/ml) 5.1 (2.0–12.0) 8.5 (1–159) 8.2 (3.7–37.3)∥ 
HOMA 1.1 (0.4–2.7) 2.29 (0.15–56.53) 1.9 (0.96–30.02) 
GH (μg/l) 0.2 (0.1–0.9)† 2.7 (0.2–6.94) 2 (0.1–8.2) 
IGF1 (ng/ml) 87 (52–102)† 32 (25–112) 135 (69–371)§ 
Fasting ghrelin (pg/ml) 643 (523–2163)* 539 (309–1262) 910 (426–3305)§ 
Ghrelin after OGTT (pg/ml) 584 (493–1109)* 447 (334–1186) 860 (461–2508)§ 
Nadir ghrelin (pg/ml) 567 (442–1154)* 444 (244–1186) 843 (426–2508)§ 
AUC ghrelin (pg/ml min) 76 560 (56 160–206 385)* 63 900 (37 260–148 410) 107 595 (59 535–357 465)§ 
    
 
HOMA, homeostasis model assessment; AUC, area under the secretory curve. Ghrelin after OGTT, 120 min ghrelin after 
OGTT. *P<0.05 between patients PreT and Cont, †P<0.01 between patients PreT and Cont. §P<0.01 between patients PreT 
and 6th month PostT. ∥P<0.05 between patients PostT and Cont. 
Fasting GH (median and range) levels were higher in PreT than in Cont, 2.7 (0.2–6.9) vs 0.2 
(0.1–0.9) μg/l, P=0.001, for PreT and Cont respectively. Fasting GH (median and range) levels 
were similar in the PreT and PostT group, 2.7 (0.2–6.9) vs 2.0 (0.1–8.2) μg/l, P=NS for the PreT 
and PostT patients respectively. Fasting IGF1 (median and range) levels were lower in PreT 
patients than in Cont subjects 32 (25-48) vs 87 (52–102) ng/ml, P=0.008, for PreT patients and 
Cont subjects respectively. Fasting IGF1 levels increased after liver transplantation, 32 (25-48) vs 
135 (69–371) ng/ml, P=0.008, for the PreT and PostT patients respectively.  
 
Fasting ghrelin (median and range) levels were lower in PreT patients than in Cont, 539 (309–
1262) vs 643 (523–2163) pg/ml, P=0.045, for PreT patients and Cont respectively. Fasting ghrelin 
levels increased after liver transplantation, 539 (309–1262) vs 910 (426–3305) pg/ml, P=0.001, for 
the PreT and PostT patients respectively. Fasting ghrelin levels were similar in the PostT patients 
and Cont group. The results are presented in the figures as mean values ±s.e.m., for the sake of 
clarity and to improve the readability. Figure 1 shows fasting serum levels (mean±s.e.m.) of 
ghrelin (pg/ml) pre-transplantation and 1, 3, 6, and 12 months after liver transplantation. Fasting 
ghrelin levels increased and normalized after liver transplantation, during all the study period (12 
months) after the transplant.  
  
 
 
 
Figure 1 Fasting serum levels (mean±s.e.m.) of ghrelin (pg/ml) PreT and 1, 3, 6, and 12 
months post liver transplantation. *P<0.05 between PreT and PostT patients at any time 
point.  
Liver function indices, MELD score and Child-Pugh score, albumin, and bilirubin completely 
normalized after liver transplantation (Table 2).  
Serum levels after oral glucose 
Glucose was higher in PreT patients than in the Cont group after the OGTT. At 120 min after 
the OGTT, glucose was higher in PreT patients than in the Cont group, 236 (93–346) vs 95 (57–
164) mg/dl, for PreT and Cont respectively, P=0.001. Glucose levels at any time point after the 
OGTT were similar in the PreT and PostT patients (Fig. 2a, mean values ±s.e.m). Insulin levels 
were similar in the PreT patients and Cont group. The AUC of insulin was similar in PreT patients 
and Cont, 4900 (1893–245 700) vs 4107 (2068–12 441) μU/ml min, for PreT and Cont 
respectively, P=NS. Insulin levels were higher at time points 90 and 120 min after OGTT in the 
PreT when compared with the PostT group (Fig. 2b, mean values ±s.e.m). The AUCs of insulin 
was higher in the PreT when compared with the PostT group, 4900 (1893–245 700) vs 3752 
(1893–24 570) μUI/ml min, for the PreT and PostT group respectively, P=0.011. Figure 2a and b 
show serum glucose and insulin levels (mean values ±s.e.m.) in Cont subjects, PreT and PostT 
patients during the OGTT.  
  
 
 
 
Figure 2 (a) Mean±s.e.m. plasma glucose (mg/dl) in controls, liver failure 
patients pretransplantation, and 6th month posttransplantation during the oral 
glucose tolerance test. +P<0.05 between controls and 6th month 
posttransplantation patients at that time points. ^P<0.05 between controls and 
pretransplantation or 6th month posttransplantation patients at that time points. 
(b) Mean±s.e.m. serum insulin levels (μUI/ml) in controls, liver failure patients 
pretransplantation, and 6th month posttransplantation during the oral glucose 
tolerance test. +P<0.05 between controls and 6th month posttransplantation 
patients at that time point. *P<0.05 between pretransplantation and 6th month 
posttransplantation patients at that time points.  
 
  
Ghrelin levels decreased during the OGTT, and nadir ghrelin levels were lower than fasting 
total ghrelin levels for PreT patients, Cont and PostT patients; PreT: 539 (309–1262) vs 444 (244–
1186) pg/ml, for fasting and nadir ghrelin respectively, P=0.001; Cont: 643 (523–2163) vs 567 
(442–1154) pg/ml, for fasting and nadir ghrelin respectively, P=0.008; PostT: 910 (426–3305) vs 
843 (426–2508) pg/ml, for fasting and nadir ghrelin respectively, P=0.008. As shown in Fig. 3, the 
response of post-OGTT ghrelin levels (mean values ±s.e.m.) in hepatic failure patients was similar 
to normal subjects, in both groups, PreT and PostT, ghrelin levels decreased during the OGTT. 
 
 
 
Figure 3 Mean±s.e.m. serum ghrelin levels (pg/ml) in controls, liver failure patients 
pretransplantation, and 6th month posttransplantation during the oral glucose tolerance 
test. *P<0.05 between controls and pretransplantation patients and P<0.01 between 
pretransplantation and 6th month posttransplantation patients.  
Ghrelin was lower in the PreT patients than in the Cont group after the OGTT. The AUCs of 
total ghrelin were lower in the PreT patients than in the Cont group, 63 900 (37 260–148 410) vs 
76 560 (56 160–206 385) pg/ml min, for PreT and Cont respectively, P=0.027. Post-OGTT ghrelin 
levels increased in the PostT patients. The AUCs of total ghrelin increased in the PostT, 63 900 
(37 260–148 410) vs 107 595 (59 535–357 465) pg/ml min, for the PreT and PostT patients, 
P=0.001. The AUC of total ghrelin was similar in the PostT patients and Cont group. Figure 3 
shows serum ghrelin levels (mean values ±s.e.m.) in the Cont group, PreT and PostT patients 
during the OGTT. Ghrelin levels were decreased in the PreT patients when compared with the 
Cont group, along all the time points. In the PostT patients, ghrelin levels increased when 
compared with the PreT patients, and were similar to the Cont group, along all the time points. 
Table 2 shows fasting and post-OGTT data (median and range) in the Cont group, PreT and PostT 
patients.  
  
Correlations 
Although a small number of patients was used for the correlation studies, in the PreT and PostT 
patients, we analyzed if there was any significant correlation between fasting ghrelin or ghrelin 
AUC levels or nadir ghrelin and age, BMI, IGF1, fasting glucose, basal GH, fasting insulin, 
insulin resistance as estimated by HOMA, glucose peak, insulin peak, glucose AUC, and insulin 
AUC. In the PreT patients, fasting total ghrelin levels negatively correlated with BMI (r=−0.492; 
P=0.023), ghrelin AUC negatively correlated with BMI (r=−0.440; P=0.046) and with insulin 
AUC (r=−0.526, P=0.014), and nadir ghrelin negatively correlated with insulin AUC (r=−0.562, 
P=0.008). Fasting ghrelin negatively correlated with fasting GH (r=−0.500, P=0.029) in the 12th 
month after liver transplantation. We were unable to discover any other significant correlation.  
Discussion 
Fasting total ghrelin levels have been studied in hepatic failure patients, with some studies 
finding increased ghrelin levels (20, 23). Atavesen et al. (20) found that in cirrhosis, serum ghrelin 
levels were increased with a corresponding decrease in serum leptin concentrations. The increase 
in ghrelin was more prominent in Child C cirrhosis, and the level was correlated with TNFα. 
Tacke et al. (23) found that ghrelin was significantly elevated and IGF1 reduced in chronic liver 
disease patients compared with healthy Cont subjects. IGF1 serum levels inversely correlated with 
Child's classification. Ghrelin levels were significantly elevated in Child C cirrhosis patients 
regardless of the etiology of liver disease. Ghrelin levels did not correlate with liver function. 
Other studies have found normal ghrelin levels (18-19, 21). Kalaitzakis et al. (19) found that 
patients with cirrhosis had similar fasting ghrelin levels to a Cont group. In contrast, patients with 
cirrhosis had higher postprandial glucose and lower ghrelin concentrations at 4 h postprandially 
than the Cont subjects. In the study by Takahashi et al. (21), plasma ghrelin levels were slightly 
but not significantly elevated in patients with liver cirrhosis when compared with Cont subjects. 
Plasma ghrelin levels were significantly correlated with BMI, but not with the severity of liver 
damage. In the study by Marchesini et al. (18), ghrelin levels were not increased in cirrhosis but 
increased with decreasing Corli score, a method used to quatify and score the amount of ingested 
food, and along the scale of anorexia/hunger. In patients with primary biliary cirrhosis, Breidert et 
al. (22) found that serum ghrelin levels were decreased in comparison with the Cont group. We 
have recently found significantly decreased fasting and post-OGTT plasma ghrelin levels in 
patients with liver failure who were candidates for transplantation when compared with Cont 
subjects (24).  
 
Discrepancies between the different studies could at least be partly explained by different 
patient selection, Cont subject selection, or both. The different causes of cirrhosis with a wide 
range of insulin sensitivity could have an impact on total ghrelin levels. Some of the patients in the 
different studies had a wide range of hepatocellular dysfunction, and were not BMI matched with 
Cont subjects. In nonalcoholic fatty liver disease, ghrelin levels have been found decreased and 
correlated with insulin resistance (29); in contrast with the patients with normal liver function, in 
the current study, the severity of liver damage was advanced. Nevertheless, both studies suggest 
that ghrelin levels are decreased in liver disease, although probably through different mechanisms. 
To our knowledge, there is only one study on postprandial ghrelin levels in liver cirrhosis. Similar 
to our results, the patients with cirrhosis had lower ghrelin concentrations at 4 h postprandially, 
although fasting ghrelin levels were similar to those of the Cont subjects (19). In normal subjects, 
there is a decrease in ghrelin levels after the OGTT (14). The response of post-OGTT ghrelin 
levels in hepatic failure patients was similar to normal subjects, in both groups, PreT and PostT, 
ghrelin levels decreased during the OGTT (24). In order to clarify the controversy over ghrelin 
levels in hepatic failure, we prospectively determined plasma ghrelin in liver failure patients 
before and after liver function normalization following transplantation. We found that decreased 
fasting and post-OGTT ghrelin levels in end-stage liver failure patients are normalized after liver 
transplantation. The response of ghrelin post-OGTT after the liver transplantation decreases in a 
similar way to the Cont group. This is the first study of ghrelin levels before and after liver 
transplantation.  
 
The mechanisms of altered fasting or postprandial ghrelin response may involve the BMI, 
glucose, insulin, GH, or all four. The concentrations of fasting ghrelin are increased in anorexia 
and cachexia but reduced in obesity (10-13, 30). Plasma ghrelin levels are negatively correlated 
with BMI (30). In the current study, the BMI was stable after liver transplantation, suggesting that 
the normalization of ghrelin levels after the transplant was not due to BMI. Insulinemia is essential 
for postprandial ghrelin suppression with glucose having an additional effect (31-33). Therefore, 
insulin resistance resulting in high postprandial glucose and insulin might be involved in the low 
ghrelin observed post-OGTT. A clearly negative association between ghrelin and insulin secretion 
has been found in humans as well as in animals by the majority of authors (11, 15, 33), although 
not by all (34-35). The insulin AUC correlated with the ghrelin AUC in liver failure patients 
before transplantation and insulin AUC decreased after the transplant, suggesting that insulin 
could participate in the normalization of ghrelin levels. We could not find any significant 
correlation between insulin and ghrelin after transplantation, probably due in part to the small 
number of patients, although other factors could contribute to ghrelin regulation. Ghrelin is a 
potent stimuli for GH secretion (7, 16) and, at least under certain physiological conditions, ghrelin 
modulates the regulation of GH secretion (36). Although the relationship between ghrelin and GH 
secretion is controversial. In acromegaly, a pathophysiological model of increased GH secretion, 
some studies have found normal ghrelin levels (37- 40), while others have found decreased ghrelin 
levels in patients with acromegaly (41-43), suggesting that increased GH could contribute toward 
the decreased ghrelin levels, in a classic feedback manner. In liver failure patients, we found 
decreased IGF1 and increased GH. After the transplant procedure, IGF1 increased and normalized, 
and there was a clear tendency toward a GH decrement. In the present study, fasting ghrelin 
negatively correlated with fasting GH in the 12th month after liver transplantation. In line with 
other studies (44), this data supports the hypothesis that GH feedback inhibits ghrelin secretion. 
Nevertheless, the number of patients used in the correlation studies was small, and the results of 
the correlation studies should be taken with great caution. Other potential confounding factors 
could be a drug-mediated effect, as the calcineurin inhibitor drugs (cyclosporine or tacrolimus) 
could decrease insulin secretion and in turn increase ghrelin, although prednisone has been found 
to decrease ghrelin levels (45). Alcohol is another possible confounding factor, as alcohol 
dependence is associated with reduced plasma ghrelin levels (46); however, our PretT patients had 
abstained from alcohol for 6 months. There was no difference in terms of ghrelin changes between 
the patients with alcoholic and nonalcoholic cirrhosis. Further studies are necessary in order to 
clarify the mechanism of altered ghrelin in cirrhosis. In any event, the presence of decreased 
fasting and post-OGTT ghrelin levels could contribute toward anorexia or other complications, in 
patients with advanced liver failure (47-48).  
 
In conclusion, we have found that decreased fasting and post-OGTT ghrelin levels in liver 
failure patients are normalized after liver transplantation.  
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